Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab

• Main Authors: Erminia Ridolo (Author), Francesco Pucciarini (Author), Maria Cristina Nizi (Author), Eleni Makri (Author), Paola Kihlgren (Author), Lorenzo Panella (Author), Cristoforo Incorvaia (Author)
• Format: Book
• Published: Taylor & Francis Group, 2020-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The introduction of biologics for the treatment of patients with refractory asthma represented a marked therapeutic advance. For more than 10 y, the only biologic available has been the monoclonal anti-IgE antibody omalizumab, reserved for patients with asthma caused by perennial allergen. In recent...